Alessandro Moretta

This inventor holds 21 USPTO granted patents and 7 published patent applications, plus 5 CIPO patents and 13 EPO patents, primarily in NK Cell Biology. Top assignees: Innate Pharma, S.a., University of Genova, Innate Pharma S.a.s.. Active years: 2005-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alessandro Moretta. Retrieved from https://idiyas.com/inventor/alessandro-moretta

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 7)

% Patents Active = 52.4

CIPO Patents = 5

EPO Patents = 13 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 9

Forward Citations = 202(Granted Patents)

Company Filing History:

Novo Nordisk-a/s Novo Alle

patents

9. 1 out of 1

Dimes - Dipartimento Do Medicina Sperimentale - Universita Degli Studi Di Genova

patent

10. 1 out of 1,853

National Institute of Health and Medical Research

patents

11. 1 out of 1

Universita Degli Studi Di Genova, Dipartimento Di Medicina Sperimentale

patent

12. 1 out of 915

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

where one patent can have more than one assignee

Years Active: 2005-2022

Loading Chart...

Areas of Expertise:

NK Cell Activity

Monoclonal Antibodies

Therapeutic Compositions

Diagnostics

Polypeptides

NKG2A

KIR Antibodies

Natural Killer Cells

4Ig-B7-H3

Bi-Specific Complexes

Proliferative Disorders

Triggering Receptors

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11365393 - Compositions and methods for regulating NK cell activity (2022-06-21),

2. 10160810 - Monoclonal antibodies against NKG2A (2018-12-25),

3. 9902936 - PAN-KIR2DL NK-receptor antibodies and their use in diagnostics and therapy (2018-02-27),

4. 9828427 - Anti-KIR3D antibodies (2017-11-28),

5. 9447185 - Compositions and methods for treating proliferative disorders (2016-09-20),

6. 9181341 - Anti-KIR3D antibodies (2015-11-10),

7. 8993319 - Monoclonal antibodies against NKG2A (2015-03-31),

8. 8981065 - Human anti-KIR antibodies (2015-03-17),

9. 8637258 - Compositions and methods for regulating NK cell activity (2014-01-28),

10. 8614307 - Nucleic acids encoding human anti-kir antibodies (2013-12-24),

11. 8465931 - Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor (2013-06-18),

12. 8133485 - Bi-specific complexes for targeting cells involved in allergic-type reactions, compositions and uses thereof (2012-03-13),

13. 8119775 - Human anti-KIR antibodies (2012-02-21),

14. 7732131 - Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor (2010-06-08),

15. 7569666 - Polypeptides associated with activatory receptors and their biological applications (2009-08-04),

Title: The Innovative Mind of Alessandro Moretta

Introduction: Alessandro Moretta, a visionary inventor hailing from Genoa, Italy, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Alessandro Moretta's latest patents include cutting-edge advancements in artificial intelligence algorithms for autonomous vehicles, smart home systems, and medical devices.

Career Highlights: With over two decades of experience in the tech industry, Moretta has held key positions in leading research institutions and multinational corporations. His expertise lies in developing disruptive technologies that have revolutionized various sectors.

Collaborations: Throughout his career, Alessandro Moretta has collaborated with top engineers, scientists, and designers from around the globe. His ability to foster creativity and teamwork has led to the successful implementation of numerous innovative projects.

Conclusion: Alessandro Moretta's relentless pursuit of innovation and his passion for pushing the boundaries of technology continue to inspire the next generation of inventors. His impact on the world of inventions is truly remarkable.

Profile summary based on public USPTO records.